



June 28, 2019

Philips Medical Systems, Inc.  
% Thomas Fallon  
Senior Director, Site Quality Transformation Lead  
Philips Medical Systems  
22100 Bothell Everett Hwy  
Bothell, Washington 98021

Re: P160029

Trade/Device Name: HeartStart OnSite Defibrillator (Model M5066A) and HeartStart Home Defibrillator (Model M5068A)

Dear Thomas Fallon:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) completed its review of your premarket approval application (PMA) and issued an approval order on June 6, 2019. We inadvertently made an error where the OnSite model number was listed as M6066A in the Trade/Device Name; however, the correct model number should be M5066A.

We hope that this error has not inconvenienced you. If you have any questions about this corrective action, please contact Jennifer Shih at 301-796-5813 or [Jennifer.Shih@fda.hhs.gov](mailto:Jennifer.Shih@fda.hhs.gov).

Sincerely,



for

Bram Zuckerman, M.D.

Director

Office of Cardiovascular Devices

Office of Product Evaluation and Quality

Center for Devices and Radiological Health



June 6, 2019

Philips Medical Systems, Inc.  
Thomas Fallon  
Senior Director, Site Quality Transformation Lead  
22100 Bothell Everett Hwy  
Bothell, Washington 98021

Re: P160029

Trade/Device Name: HeartStart OnSite Defibrillator (Model M6066A), HeartStart Home Defibrillator (Model M5068A), Primary Battery (Model M5070A), SMART Pads Cartridges (Adult Model M5071A) and Infant/Child (Model M5072A)

Product Code: NSA, MKJ (pediatric pads)

Filed: July 29, 2016

Amended: October 28, 2016, April 7, 2017, May 18, 2017, October 18, 2017, July 6, 2018, August 8, 2018, and May 10, 2019

Dear Thomas Fallon:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) for the HeartStart OnSite Defibrillator (Model M5066A) and HeartStart Home Defibrillator (Model M5068A).

The HeartStart OnSite (Model M5066A) is indicated for use on potential victims of sudden cardiac arrest with the following symptoms:

- Unconsciousness; and
- Absence of normal breathing.

The HeartStart OnSite (Model M5066A) is indicated for adults over 55 pounds (25 kg). The OnSite is also indicated for infants/children under 55 lbs (25 kg) or 8 years old when used with the optional infant/child SMART pads (Model M5072A). If Infant/Child SMART pads are not available, or you are uncertain of the child's age or weight, proceed with treatment using adult SMART pads (Model M5071A).

The HeartStart Home Defibrillator (Model M5068A) is indicated for use on potential victims of sudden cardiac arrest with the following symptoms:

- Unconsciousness; and
- Absence of normal breathing.

The HeartStart Home (Model M5068A) is indicated for adults over 55 pounds (25 kg). The Home is also indicated for infants and children under 55 lbs (25 kg) or 8 years old when used with the optional infant/child

SMART pads (Model M5072A). If Infant/Child SMART pads are not available, or you are uncertain of the child's age or weight, proceed with treatment using adult SMART pads (Model M5071A).

We are pleased to inform you that the PMA is approved. You may begin commercial distribution of the device in accordance with the conditions of approval described below.

The HeartStart Home and OnSite devices when used with the Adult SMART Pads Cartridges are for over-the-counter use. The sale and distribution of the Infant/Child SMART Pads Cartridges for use with the HeartStart Home and OnSite devices are restricted to prescription use in accordance with 21 CFR 801.109 and under section 515(d)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act (the act). The Infant/Child SMART Pads Cartridges for use with the HeartStart OnSite and Home devices are further restricted under section 515(d)(1)(B)(ii) of the act insofar as the labeling must specify the specific training or experience practitioners need in order to use the device. FDA has determined that these restrictions on sale and distribution are necessary to provide reasonable assurance of the safety and effectiveness of the device. The Infant/Child SMART Pads Cartridges for use with the HeartStart Home and OnSite devices are therefore a restricted device subject to the requirements in sections 502(q) and (r) of the act, in addition to the many other FDA requirements governing the manufacture, distribution, and marketing of devices.

Expiration dating for the SMART Pads Cartridge for Adults and Infant/Child SMART pads has been established and approved at 30 months. Expiration dating for the Primary Battery of this device has been established and approved at 4 years. This is to advise you that the protocol you used to establish this expiration dating is considered an approved protocol for the purpose of extending the expiration dating as provided by 21 CFR 814.39(a)(7).

Continued approval of the PMA is contingent upon the submission of periodic reports, required under 21 CFR 814.84, at intervals of one year (unless otherwise specified) from the date of approval of the original PMA. This report, identified as "Annual Report" and bearing the applicable PMA reference number, should be submitted to the address below. The Annual Report should indicate the beginning and ending date of the period covered by the report and should include the information required by 21 CFR 814.84.

In addition to the above, and in order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, the Annual Report must include, separately for each model number (if applicable), the number of devices sold and distributed during the reporting period, including those distributed to distributors. The distribution data will serve as a denominator and provide necessary context for FDA to ascertain the frequency and prevalence of adverse events, as FDA evaluates the continued safety and effectiveness of the device.

You have agreed to provide the following non-clinical information as part of the annual report, which may be followed by a PMA supplement where applicable.

1. The number of devices returned to the applicant for cause from domestic sources, with a breakdown into:
  - a. Those returned for normal end-of-life; and

- b. Those returned with any alleged failures or malfunctions, including a summary of root causes and the frequency of occurrence for each identified root cause.
2. The number of replacement defibrillation pads and replacement batteries issued to customers domestically for all causes.
3. A summary of information available to you related to individual domestic uses of your device that may include, but is not limited to:
  - a. Defibrillation success and the number of shocks required for success; and
  - b. Identification of any error codes or malfunctions during use and their related MDR number.
4. A listing of any safety alerts, technical service bulletins, user communications, or recalls for devices under this PMA.

In addition to the conditions of approval above, you have agreed to implement alternate controls to address violations of the current good manufacturing practice requirements of the Quality System regulations found at Title 21, Code of Federal Regulations, Part 820. Continued approval of P160029 is contingent on implementing the alternate controls and providing evidence of effective implementation. This variance is conditioned on Philips making timely progress to address – to the agency’s satisfaction – the violations identified in previous and any further inspections covering the device under this PMA.

This is a reminder that as of September 24, 2014, class III devices are subject to certain provisions of the final Unique Device Identification (UDI) rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, 21 CFR 814.84 (b)(4) requires PMA annual reports submitted after September 24, 2014, to identify each device identifier currently in use for the subject device, and the device identifiers for devices that have been discontinued since the previous periodic report. It is not necessary to identify any device identifier discontinued prior to December 23, 2013. Combination Products may also be subject to UDI requirements (see 21 CFR 801.30). For more information on these requirements, please see the UDI website, <http://www.fda.gov/udi>.

Before making any change affecting the safety or effectiveness of the PMA device, you must submit a PMA supplement or an alternate submission (30-day notice) in accordance with 21 CFR 814.39. All PMA supplements and alternate submissions (30-day notice) must comply with the applicable requirements in 21 CFR 814.39. For more information, please refer to the FDA guidance document entitled, "Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process" <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089274.htm>.

You are reminded that many FDA requirements govern the manufacture, distribution, and marketing of devices. For example, in accordance with the Medical Device Reporting (MDR) regulation, 21 CFR 803.50 and 21 CFR 803.52 for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products, you are required to report adverse events for this device. Manufacturers of medical devices, including in vitro diagnostic devices, are required to report to FDA no later than 30 calendar days after the

day they receive or otherwise becomes aware of information, from any source, that reasonably suggests that one of their marketed devices:

1. May have caused or contributed to a death or serious injury; or
2. Has malfunctioned and such device or similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

Additional information on MDR, including how, when, and where to report, is available at <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> and on combination product postmarketing safety reporting is available at (see <https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm>).

In accordance with the recall requirements specified in 21 CFR 806.10 for devices or the postmarketing safety reporting requirements (21 CFR 4, Subpart B) for combination products, you are required to submit a written report to FDA of any correction or removal of this device initiated by you to: (1) reduce a risk to health posed by the device; or (2) remedy a violation of the act caused by the device which may present a risk to health, with certain exceptions specified in 21 CFR 806.10(a)(2). Additional information on recalls is available at <http://www.fda.gov/Safety/Recalls/IndustryGuidance/default.htm>.

CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. CDRH will notify the public of its decision to approve your PMA by making available, among other information, a summary of the safety and effectiveness data upon which the approval is based. The information can be found on the FDA CDRH Internet HomePage located at <http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/default.htm>. Written requests for this information can also be made to the Food and Drug Administration, Dockets Management Branch, (HFA-305), 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The written request should include the PMA number or docket number. Within 30 days from the date that this information is placed on the Internet, any interested person may seek review of this decision by submitting a petition for review under section 515(g) of the act and requesting either a hearing or review by an independent advisory committee. FDA may, for good cause, extend this 30-day filing period.

Failure to comply with any post-approval requirement constitutes a ground for withdrawal of approval of a PMA. The introduction or delivery for introduction into interstate commerce of a device that is not in compliance with its conditions of approval is a violation of law.

You are reminded that, as soon as possible and before commercial distribution of your device, you must submit an amendment to this PMA submission with a copy of all final labeling. Final labeling that is identical to the labeling approved in draft form will not routinely be reviewed by FDA staff when accompanied by a cover letter stating that the final labeling is identical to the labeling approved in draft form. If the final labeling is not identical, any changes from the final draft labeling should be highlighted and explained in the amendment.

All required documents should be submitted, unless otherwise specified, to the address below and should reference the above PMA number to facilitate processing.

U.S. Food and Drug Administration  
Center for Devices and Radiological Health  
Document Control Center - WO66-G609  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002

If you have any questions concerning this approval order, please contact Jennifer Shih at 301-796-5813 or [Jennifer.Shih@fda.hhs.gov](mailto:Jennifer.Shih@fda.hhs.gov).

Sincerely,

  
for

Bram Zuckerman, M.D.

Director

Office of Cardiovascular Devices

Office of Product Evaluation and Quality

Center for Devices and Radiological Health